Neuropeptide Y1 and Y5 Receptor Antagonists as Potential Anti-Obesity Drugs: Current Status

E-ISSN： 1875-5607|14|11|896-919

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.14, Iss.11, 2014-10, pp. : 896-919

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NPY Y1 and Y5 Receptor Selective Antagonists as Anti-Obesity Drugs

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 17, 2007-01 ,pp. : 1721-1733

Bentham Science Publishers

Access to resources Recommend Favorite

Neuropeptide Y receptor antagonists in obesity

By Gehlert D.R. Hipskind P.

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 12, 1997-12 ,pp. : 1827-1838

Informa Healthcare

Access to resources Recommend Favorite

Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status

By Parker E. Van Heek M. Stamford A.

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 173-187

Elsevier

Access to resources Recommend Favorite

The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents

Current Topics in Medicinal Chemistry, Vol. 9, Iss. 6, 2009-04 ,pp. : 482-503

Bentham Science Publishers

Access to resources Recommend Favorite

Neuropeptide Y receptor antagonists

By Ling A.L.

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 4, 1999-04 ,pp. : 375-384

Informa Healthcare

Access to resources Recommend Favorite